Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Sep;14(5):526-34.
doi: 10.1097/MOH.0b013e3282ab98df.

Update on the Management of Immune Thrombocytopenic Purpura in Children

Affiliations
Review

Update on the Management of Immune Thrombocytopenic Purpura in Children

Michael D Tarantino et al. Curr Opin Hematol. .

Abstract

Purpose of review: Since the publication of management guidelines from the American Society of Hematology (1996) and the British Committee for Standards in Haematology (2003), issues surrounding the diagnosis and treatment of immune thrombocytopenic purpura in children continue to evolve. Reports of the last decade are reviewed here.

Recent findings: Few data support a change in the diagnostic approach to childhood immune thrombocytopenic purpura. Recent publications have again challenged the need to treat minimally symptomatic children with severely low platelet counts and confirmed that anti-D immune globulin is a front-line treatment option. The management of chronic disease in children is essentially the same as in acute cases that become persistent or refractory to treatment. During the past 3 years, noncontrolled studies have suggested that rituximab may be useful for persistent disease. Elsewhere, encouraging evidence suggests that the effect of splenectomy for children is durable in the long term.

Summary: The decision to treat or only observe the minimally symptomatic child with severe thrombocytopenia remains controversial. This ongoing debate has served as a mandate to develop and implement clinical scoring and quality of life tools in treatment and clinical trial design. Meanwhile, experiences with adult cases have introduced new drug treatment options for children, especially those with chronic disease and significant bleeding.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

MeSH terms

Feedback